You would like to read
- TCG Digital Introduces tcg mcube 4.0 to Turbocharge CX-A Step towards the Next Orbit
- S H Kelkar rises after strong Q2 business update
- D & H India reports consolidated net profit of Rs 0.28 crore in the December 2020 quarter
- D & H India reports consolidated net loss of Rs 0.91 crore in the June 2020 quarter
- D & H India reports consolidated net loss of Rs 0.39 crore in the September 2020 quarter
Kolkata (West Bengal) [India], February 4 (ANI/PRNewswire): TCG Lifesciences Pvt. Ltd., a company controlled by New York-based The Chatterjee Group ("TCG"), has announced today the expansion of its operations in the USA with the establishment of TCG GreenChem Inc., a subsidiary of TCG Lifesciences Pvt. Ltd, to provide CDMO services to global clients. TCG GreenChem, Inc., offers seamless CMC development services including process research & development and delivery of cGMP APIs.
It aims at utilizing its deep expertise in areas of automated catalysis/reaction screening, reaction optimization, and continuous chemistry to support the needs of the big pharma and biotech industry. It has a robust pipeline of projects with its customers to manage their entire portfolios, offering integrated CMC and supply of APIs from early clinical trials to commercialization.
TCG GreenChem, Inc. is developing novel, efficient and low-cost processes for selected COVID-19 virus related medicines and other antiviral drugs using new technologies and process schemes under contract with research foundations/hospitals, US Government, and selected biotech companies. It is also engaged with developing several selected drugs with backward integration all the way to the starting materials within US shores. TCG GreenChem, Inc. operates out of a 3,000 SFT lab space in VCU's Biotechnology Research Park with access to state-of-the-art facilities. It also occupies 54,000 SFT lab/office space in the Princeton South Corporate Center, a one-of-a-kind process research and development facility including cGMP capabilities.
Swapan Bhattacharya, Managing Director, TCG Lifesciences Pvt. Ltd. commented, "The priority of our customers today is to find ways to leverage their external partners to fill up a large part of their product development needs. In order to become their preferred partners, we need to provide high quality, efficient and low-cost services which are only possible if we deploy high-end talents and skills that can drive innovation. TCG GreenChem has an exceptional management team, technological expertise and know-how, which is critical for the development of architecturally complex intermediates and APIs by utilizing state-of-the-art synthetic organic chemistry."
Dr Chris H Senanayake, CEO and CSO, TCG GreenChem, Inc. added, "We are excited to be a part of TCG Lifesciences Pvt. Ltd., as they are highly valued by their pharmaceutical partners and have a reputation of embracing innovation and high-end technology which are the cornerstones of the TCG GreenChem's strategy. Our mission is to create a "technology innovator" CDMO, to partner with the pharmaceutical, biotechnology, and generic industries in delivering integrated, accelerated, and economical services utilizing green sustainable technologies with a global footprint. Leveraging our knowledge of drug development and commercialization, we want to be the Drug Development Engine "Accelerating Molecules to Medicines" by advancing preclinical candidates into phase I and beyond, for our clients and partners."
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
DISCLAIMER
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
